Beta Bionics, Inc.
BBNX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $27 | $23 | $18 | $20 |
| % Growth | 17.3% | 31.7% | -13.7% | – |
| Cost of Goods Sold | $12 | $11 | $9 | $9 |
| Gross Profit | $15 | $13 | $9 | $12 |
| % Margin | 55.5% | 53.8% | 50.9% | 57.2% |
| R&D Expenses | $8 | $9 | $8 | $9 |
| G&A Expenses | $8 | $8 | $7 | $5 |
| SG&A Expenses | $24 | $24 | $20 | $16 |
| Sales & Mktg Exp. | $16 | $16 | $13 | $11 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $32 | $32 | $28 | $25 |
| Operating Income | -$17 | -$20 | -$19 | -$13 |
| % Margin | -62.5% | -85.5% | -105.7% | -63.8% |
| Other Income/Exp. Net | $3 | $3 | -$10 | -$5 |
| Pre-Tax Income | -$14 | -$17 | -$29 | -$18 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14 | -$17 | -$29 | -$18 |
| % Margin | -52.1% | -72.6% | -162.5% | -88.6% |
| EPS | -0.33 | -0.39 | -0.93 | -0.42 |
| % Growth | 15.4% | 58.1% | -121.4% | – |
| EPS Diluted | -0.33 | -0.39 | -0.93 | -0.42 |
| Weighted Avg Shares Out | 44 | 43 | 31 | 43 |
| Weighted Avg Shares Out Dil | 44 | 43 | 31 | 43 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $2 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$14 | -$16 | -$18 | -$18 |
| % Margin | -49.6% | -69.8% | -102.3% | -86% |